The European Commission has sent a statement of objections to Teva as it has agreed not to market a cheaper generic drug to compete Cephalon's Modafinil drug used to treat sleep disorders. According to the agreement Cephalon would pay Teva on the condition that the latter would not market its generic drug to the market in the European Economic Area until 2012 October. The European Commission is of the opinion that the patients and health service budgets in the EU may have suffered from the agreement as it may have delayed entry of a cheaper drug into the market. The press release dated 17 July 2017 about the case is available via http://europa.eu/rapid/press-release_IP-17-2063_en.htm